Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharm
March 08 2007 - 1:56AM
UK Regulatory
Mechelen, Belgium; 8 March 2007 - Galapagos NV (Euronext & LSE: GLPG)
announced today that its service division, BioFocus DPI, has entered
into an agreement to supply small molecule compounds for drug
discovery to the Johnson & Johnson Pharmaceutical Research &
Development Division of Janssen Pharmaceutica NV (J&JPRD). Under the
terms of the two-year agreement, BioFocus DPI will provide access to
compounds from its SoftFocus small molecule libraries and will also
generate customer specific compound library sets for use in J&JPRD's
drug discovery programs. Financial terms were not disclosed.
"This supply agreement is a natural expansion of our drug discovery
relationship with J&JPRD. It will give J&JPRD access to highly
targeted drug building blocks for their drug discovery programs,"
said Onno van de Stolpe, Chief Executive Officer of Galapagos.
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone and joint diseases, cachexia, and menopausal hot
flashes. Its division BioFocus DPI offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates. BioFocus DPI also provides adenoviral reagents for rapid
identification and validation of novel drug targets, compound
libraries for drug screening as well as chemogenomics and ADMET[1]
database products to select targets and compounds. Galapagos
currently employs 450 people and operates facilities in eight
countries, with global headquarters in Mechelen, Belgium. More
information about Galapagos and BioFocus DPI can be found at
www.glpg.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 290 980 28
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.
SoftFocus� is a registered trademark of Galapagos NV and/or its
affiliates.
[1] ADMET is the acronym for Absorption, Distribution, Metabolism,
Excretion, and Toxicity: Meeting parameters against these five
criteria is critical to the success of a pharmaceutical compound as a
drug.
Copyright � Hugin ASA 2007. All rights reserved.
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024